Cantor Fitzgerald Initiates Coverage on Isis Pharmaceuticals (ISIS) with a Buy; Milestones & Potential Near-term Catalysts
Tweet Send to a Friend
Cantor Fitzgerald initiates coverage on Isis Pharmaceuticals (Nasdaq: ISIS) with a Buy. Price target $28.
Cantor analyst says, "Isis, the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Cantor analyst says, "Isis, the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
